The Latest

RegenMed is proud to announce that Ms Laura Prey has joined our corporate board of directors.Ms. Prey brings to the RegenMed board more than three decades of senior-level IT experience in the healthcare, insurance and financial industries. This experience will be invaluable in helping management shape the strategic direction of its patented Circles platforms as the Company serves larger enterprise clients.As a proven visionary leader in Fortune 500 as well as small to mid-size companies, Laura established an enviable track record of accelerating the delivery of innovative technology solutions despite complex business and technical challenges.Laura most recently served as a consultant to the CIO of Optum Florida, helping to drive strategy and agile technology delivery across a wide portfolio of operations and clinical products. Prior to that, she held the position of Vice President, Information Technology at Thrivent, a Fortune 500 Financial Services company where she led technology for life, health and annuity operations.Prior to Thrivent, Ms. Prey oversaw the successful delivery of complex software products for WPS Insurance in connection with the U.S. Department of Defense’s Tricare offering, which serves millions of members of the U.S. military and their families.Ms. Prey received a Bachelor of Business Administration degree in Management Information Systems and an MBA from the University of Wisconsin Madison.

Missed our "Last Investors Webinar"? No worries! The recordings are now available for you to watch at your convenience. Dive into insightful discussions with our company leaders, explore innovative investment strategies, and gain valuable knowledge about the healthcare data market.Whether you’re a seasoned investor or just starting out, this is an opportunity you won’t want to miss!Access the full recordings and empower your investment journey today!

Data: The World’s Most Precious Commodity In the 21st Century, data is the raw material upon which all value-added transactions depend. Manufacturing, , finance, transportation, energy and countless other industries all heavily rely on data to innovate, compete and indeed survive. This is nowhere more true than in healthcare. The $60 billion healthcare data market is growing at over 11% per year. The largest consumer of data will be AI, if it is not already. Indeed, AI is fast running out of training data. This puts a premium on private sources of relevant and high quality data. As with all raw material, clear proof of data ownership is critical. Who Owns That Data? Failure to establish data ownership invites litigation, and the inability to successfully monetize or otherwise use it. For example, in December 2023 the New York Times sued OpenAI and Microsoft for copyright infringement, seeking billions of dollars in damages. This month, Thomson Reuters won a landmark AI copyright infringement case. The federal court held that the defendant used content from Thomson Reuters to develop a competing AI-driven legal research tool. The judge ruled that the defendant’s actions did not qualify as "fair use" under U.S. copyright law. This landmark decision underscores the legal protections surrounding the use of copyrighted materials in AI training and development. This Is Yet One More Challenge For “Big Data” And Healthcare AI Models AI in medicine is already here, and will only become more pervasive. However, the data on which AI healthcare models train is typically of poor quality. Problems include incompleteness, inability to audit original sources, no or irrelevant clinical context, data “cleaning” and other unknown manipulations, irreconcilable data conflicts, no correlated outcomes measures, and stale or undated information. Most of today’s $60 bn. data market represents the exchange and repackaging of such “big data”. AI error rates and “hallucinations” are thus not only inevitable in most AI healthcare solutions, they are dangerous in specific applications such as clinical decision-making. But now there is a deeper problem – who owns the various bits and pieces of data making up a “big data” dataset? EMR companies, medical society registries, hospital systems, researchers, payers, AI start-ups are among the many entities who may have contributed and will claim ownership. The weaknesses of “big data” structures, coupled with competing ownership claims, will make it an increasingly unattractive choice for healthcare data consumers, including AI models. The Circles Solution RegenMed’s Circle datasets are generated and maintained in a closed system which maintains their coherence, transparency, and auditability. They are high-quality – both statistically and clinically significant – with clear ownership and monetization rights vested in the dataset creators. Real world data is likely to become one of the most critical categories of all healthcare data. It will be key to supporting value based medicine, lower costs, faster lab-to-bedside clinical translation, and health equity. RegenMed is well positioned to capture a significant portion of this market.

‍The Large and Growing MarketHealthcare is undergoing a paradigm shift. With rising chronic diseases, escalating healthcare costs, and growing dissatisfaction with conventional treatments, patients are turning to Complementary and Alternative Medicine (CAM). CAM is no longer seen as fringe medicine. It is now a mainstream movement, with increasing adoption in hospitals, clinics, and even corporate wellness programs. Over 50% of U.S. physicians recommended at least one complementary health approach to their patients within a 12-month period. 1One-third of Americans use CAM alongside conventional treatments. In Europe, 25-50% of the population uses CAM therapies, including homeopathy, naturopathy, and herbal medicine. In Asia, Traditional Chinese Medicine (TCM) and Ayurveda are deeply embedded in cultural and medical systems. 2The Global CAM Market is valued at $100–$400 billion, with a projected growth rate of 15–25%. The U.S. CAM market is valued at over $50 billion 3. Factors driving this growth include:Patients are more proactive about their health.More people are seeking alternative solutions for pain, inflammation, and metabolic disorders.CAM aligns with the booming self-care, fitness, and mental health movements.AI-powered health platforms, wearable biofeedback devices, and personalized wellness programs are making CAM more accessible.Major corporations, insurance providers, and even governments are beginning to integrate CAM into healthcare policies and benefits. 4True healthcare innovation lies in integration — combining the best of conventional medicine with evidence-based CAM therapies.Chronic Disease Management: CAM therapies like acupuncture, herbal medicine, and functional nutrition help manage diabetes, cardiovascular diseases, and autoimmune disorders without heavy reliance on pharmaceuticals.Pain & Opioid Crisis Solutions: Chiropractic care, acupuncture, and red light therapy offer non-drug alternatives for pain management, reducing opioid dependence.Mental Health & Stress Reduction: Meditation, breathwork, and biofeedback therapies help treat anxiety, depression, PTSD, and insomnia — often as effectively as medication.Personalized & Preventive Healthcare: Functional and integrative medicine focus on root causes rather than symptom suppression, reducing long-term healthcare costs.Patient Demand & Market Trends: Hospitals and clinics adopting CAM see higher patient satisfaction, improved treatment outcomes, and increased revenue. 5Several world-renowned institutions, such as Mayo Clinic, Cleveland Clinic, and Johns Hopkins, have already integrated CAM into their healthcare offerings—proving that a blended approach is the future of medicine.RegenMed Is Strongly Positioned To BenefitThere is very little data on integrative, complementary, or alternative medicine procedures. Circles represent a clinical grade yet low-cost approach to generating statistically significant datasets for any individual or combination of procedures. RegenMed is already working with doctors around the world in developing such datasets. They will be critical to:Regulation & Standardization: Governments are creating guidelines to ensure CAM therapies meet safety and efficacy standards.Insurance Expansion: More insurance companies are covering CAM services, recognizing their cost-effectiveness.AI & Digital CAM Platforms: Personalized health recommendations using AI-driven diagnostics.Mainstream Adoption of Holistic Wellness: Corporations are investing in employee wellness programs that integrate CAM.Psychedelic-Assisted Therapy: Psilocybin and MDMA treatments are gaining momentum for mental health breakthroughs.‍‍

Nate Anderson will interview Michael Tierney, Co-Founder and CEO, as well as Dolph Courchaine, Chief Information and Technology Officer.Topics will include:Market dynamicsCompetitive positioningValuation models Open Q & A sessionAnd more‍Date: Tuesday, February 18Time: 6:30 PM EST‍This campaign closes on March 6.Claim Your Place!